In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

The Minnesota Department of Health recently unveiled a pivotal report on the 340B drug pricing program, which provides ...

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities that receive the discounts from drug manufacturers.

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

In its zeal to shrink the federal government, will the coming Trump administration disrupt a discount drug program that underpins the rural hospitals serving the communities that gave him their ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.